Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New liquid embolic shows promise for prostate troubles

NCT ID NCT07255508

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a liquid material called SQUIDPERI for a procedure that blocks blood flow to the prostate (prostatic artery embolization) in men with an enlarged prostate. The goal is to see if it works better than standard particles at easing urinary symptoms like frequent or weak urination. About 100 men will take part, and success is measured by symptom scores at 3 months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2025

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Nonvulnerable men suffering from LUTS related to BPH and eligible to PAE.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Patient scheduled for a PAE using SquidPERI as part of routine care * Patient informed who signed the informed consent form * French social security affiliation * Good understanding of the French language Exclusion Criteria: * Patient unwilling or unlikely to comply with FU schedule * Known severe allergy to iodine * Known severe hepatic impairment * Vulnerable patient populations (such as patient under guardianship, curatorship, deprived of liberty) * Patient that already had a PAE * Patient on AME (state medical aid) * Participation in any interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Benign prostate hypertrophy(BPH) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Benign prostate hypertrophy(BPH)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Arnaud de Villeneuve (Service Imagerie diagnostique et interventionnelle)

    Montpellier, 34295, France

  • Hôpital Européen Georges Pompidou - AP-HP (Radiologie Interventionnelle vasculaire et oncologique)

    Paris, 75015, France

  • Hôpital Timone (Radiologie adultes et neuroradiologie)

    Marseille, 13385, France

  • Institut Cardiovasculaire de Strasbourg (ICS) - Clinique Rhena (Radiologie interventionnelle vasculaire et oncologique)

    Strasbourg, 67000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.